Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).

Luciano J. Costa,Hang Quach,Keith Stockerl-Goldstein,Bradley Augustson,Geraldine Ferron-Brady,Bikramjit Chopra,Allie Moore,Sophia Hudson,Jiangxiu Zhou,Veronique Bragulat,Mala Talekar,Joanna Opalinska

Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).

2019

Luciano J. Costa
Hang Quach
Keith Stockerl-Goldstein
Bradley Augustson
Geraldine Ferron-Brady
Bikramjit Chopra
Allie Moore
Sophia Hudson
Jiangxiu Zhou
Veronique Bragulat
Mala Talekar
Joanna Opalinska

TPS8053Background: B-cell maturation antigen (BCMA) is a validated therapeutic target in Multiple Myeloma (MM). GSK2857916 is a humanized (IgG1) anti-BCMA monoclonal antibody conjugated to monometh...

Keywords:

Refractory Multiple Myeloma
Antigen
Monoclonal antibody
Pathology
Oncology
Internal medicine
Medicine
Tolerability
Multiple myeloma
open label
safety tolerability
relapsed refractory
phase i ii
standard of care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations